您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (12): 23-28.doi: 10.6040/j.issn.1671-7554.0.2020.0817

• • 上一篇    下一篇

miR-203靶向Survivin抑制卵巢癌细胞增殖、迁移与侵袭

王宝金1,赵欣欣1,李霞1,马倩1,王新月1,孙阳2,史中娜1   

  1. 1.郑州大学第三附属医院妇科, 河南省卵巢恶性肿瘤国际联合实验室, 河南 郑州 450052;2.福建省立医院妇科, 福建 福州 350001
  • 发布日期:2020-12-08
  • 通讯作者: 王宝金. E-mail:307797362@qq.com
  • 基金资助:
    河南省科技计划项目(192102310067,GHB2019048)

miR-203 targeting Survivin to inhibit the proliferation, migration and invasion of ovarian cancer cells

WANG Baojin1, ZHAO Xinxin1, LI Xia1, MA Qian1, WANG Xinyue1, SUN Yang2, SHI Zhongna1   

  1. 1. Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, Henan International Joint Laboratory of Ovarian Malignancies, Zhengzhou 450052, Henan, China;
    2. Department of Gynecology, Fujian Provincial Hospital, Fuzhou 350001, Fujian, China
  • Published:2020-12-08

PDF (PC)

503

摘要： 目的 探讨miR-203靶向抑制Survivin对卵巢癌SKOV3及OVCAR3细胞增殖、迁移及侵袭的影响。 方法 构建过表达miR-203、Survivin及空白对照组的慢病毒载体,转染卵巢癌SKOV3和OVCAR3细胞,嘌呤霉素筛选后构建空白对照组、过表达miR-203组、过表达Survivin组及过表达miR-203联合Survivin组卵巢癌细胞系。Western blotting方法测定各组卵巢癌细胞中Survivin及上皮-间质转化(EMT)相关蛋白的表达;MTT和平板克隆实验检测卵巢癌细胞增殖能力的改变;Transwell实验检测对细胞迁移和侵袭能力的影响。 结果 (1) 过表达miR-203抑制Survivin的表达及EMT(P<0.05);(2) MTT、平板克隆实验及transwell实验显示,与空白对照组相比,过表达miR-203组能够抑制卵巢癌细胞的增殖、迁移和侵袭(P<0.05);而过表达Survivin逆转了miR-203对卵巢癌的抑制作用(P<0.05)。 结论 miR-203通过靶向Survivin抑制EMT从而抑制卵巢癌的增殖、迁移及侵袭,miR-203/Survivin/EMT轴有望成为卵巢癌治疗的新靶点。

关键词: 卵巢癌, miR-203, Survivin, 上皮-间质转化

Abstract: Objective To investigate the effects of miR-203 targeting Survivin on the proliferation, migration and invasion of ovarian cancer cells SKOV3 and OVCAR3. Methods After miR-203 over-expressing group, Survivin over-expressing group and black control group of lentiviral vectors were constructed, the SKOV3 and OVCAR3 cells were transfected. After puromycin screening, the blank control group, miR-203 over-expressing group, Survivin over-expressing group, and miR-203 over-expressing plus Survivin group were established. The expressions of Survivin and epithelial-mesenchymal transition(EMT)-related proteins in each group were detected with Western blotting. The proliferation of cells was detected with MTT and plate clone formation assay. The cell migration and invasion were detected with Transwell assay. Results miR-203 over-expression inhibited the expressions of Survivin and EMT(P<0.05). MTT, plate clone formation and Transwell assay illustrated that, compared with the blank control group, the miR-203 over-expressing group had inhibited cell proliferation, migration, and invasion(P<0.05), while the Survivin over-expressing group reversed the inhibitory effects of miR-203(P<0.05). Conclusion miR-203 can inhibit EMT by targeting Survivin to inhibit the proliferation, migration, and invasion of ovarian cancer cells. The miR-203/Survivin/EMT axis is expected to be a new target for the treatment of ovarian cancer.

Key words: Ovarian cancer, miR-203, Survivin, Epithelial-mesenchymal transition

中图分类号: 

  • R737.31
[1] 陆衡, 刘延国, 李曙光, 等. YKL-40对卵巢癌SKOV-3细胞迁移能力的影响[J]. 山东大学学报(医学版), 2017, 55(1): 33-38. LU Heng, LIU Yanguo, LI Shuguang, et al. Regulation of epithelial ovarian carcinoma SKOV-3 cell migration by YKL-40 and the underlying mechanism [J]. Journal of Shandong University, 2017, 55(1): 33-38.
[2] Wu X, Liu X. Analysis of the expression of D-dimer, CD147 and miR203 and their correlation in gastric cancer[J]. Pak J Med Sci, 2019, 35(2): 443-447.
[3] Piasecka D, Braun M, Kordek R, et al. MicroRNAs in regulation of triple-negative breast cancer progression[J]. J Cancer Res Clin Oncol, 2018, 144(8): 1401-1411.
[4] You A, Fu L, Li Y, et al. MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3[J]. Cell Cycle, 2020, 19(10): 1105-1121.
[5] Wang Q, Yang G, Jiang Y, et al. XB130, regulated by miR-203, miR-219, and miR-4782-3p, mediates the proliferation and metastasis of non-small-cell lung cancer cells[J]. Mol Carcinog, 2020, 59(5): 557-568.
[6] Zeng S, Liu S, Feng J, et al. MicroRNA-32 promotes ovarian cancer cell proliferation and motility by targeting SMG1[J]. Oncol Lett, 2020, 20(1): 733-741.
[7] Zhang Y, Zhou SY, Yan HZ, et al. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1[J]. Sci Rep, 2016, 6: 19995. doi:10.1038/srep19995.
[8] Le F, Luo P, Ouyang Q, et al. LncRNA WT1-AS downregulates Survivin by upregulating miR-203 in papillary thyroid carcinoma[J]. Cancer Manag Res, 2020, 12: 443-449. doi: 10.2147/CMAR.S232294.eCollection 2020.
[9] Wang B, Li X, Zhao G, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway[J]. J Exp Clin Cancer Res, 2018, 37(1): 235-243.
[10] Qian XQ, Tang SS, Shen YM, et al. Notch1 affects chemo-resistance through regulating epithelial-mesenchymal transition(EMT)in epithelial ovarian cancer cells[J]. Int J Med Sci, 2020, 17(9): 1215-1223.
[11] Scalici JM, Arapovic S, Saks EJ, et al. Mesothelium expression of vascular cell adhesion molecule-1(VCAM-1)is associated with an unfavorable prognosis in epithelial ovarian cancer(EOC)[J]. Cancer, 2017, 123(6): 977-984.
[12] Chen X, Zhang J, Zhang Z, et al. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma[J]. Hum Pathol, 2013, 44(11): 2373-2384.
[13] Ghafouri-Fard S, Shoorei H, Taheri M. miRNA profile in ovarian cancer[J]. Exp Mol Pathol, 2020, 113: 104381. doi:10.1016/j.yexmp.2020.104381.
[14] Kim JS, Choi DW, Kim CS, et al. MicroRNA-203 induces apoptosis by targeting bmi-1 in YD-38 oral cancer cells[J]. Anticancer Res, 2018, 38(6): 3477-3485.
[15] Zhang K, Dai L, Zhang B, et al. miR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells[J]. J Cell Physiol, 2015, 230(4): 903-910.
[16] Gao P, Wang S, Jing F, et al. microRNA-203 suppresses invasion of gastric cancer cells by targeting ERK1/2/Slug/ E-cadherin signaling[J]. Cancer Biomark, 2017, 19(1): 11-20.
[17] Deng B, Wang B, Fang J, et al. MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2[J]. Sci Rep, 2016, 6: 28301. doi:10.1038/srep28301.
[18] Chi Y, Jin Q, Liu X, et al. miR-203 inhibits cell proliferation, invasion, and migration of non-small-cell lung cancer by downregulating RGS17[J]. Cancer Sci, 2017, 108(12): 2366-2372.
[19] Shen J, Zhang J, Xiao M, et al. miR-203 Suppresses bladder cancer cell growth and targets twist[J]. Oncol Res, 2018, 26(8): 1155-1165.
[20] Lin J, Wang L, Gao J, et al. MiR-203 inhibits estrogen-induced viability, migration and invasion of estrogen receptor α-positive breast cancer cells[J]. Exp Ther Med, 2017, 14(3): 2702-2708.
[21] Martínez-García D, Manero-Rupérez N, Quesada R, et al. Therapeutic strategies involving survivin inhibition in cancer[J]. Med Res Rev, 2019, 39(3): 887-909.
[22] He XJ, Zhang Q, Ma LP, et al. Aberrant alternative polyadenylation is responsible for Survivin up-regulation in ovarian cancer[J]. Chin Med J(Engl), 2016, 129(10): 1140-1146.
[23] Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018, 13: 395-412. doi: 10.1146/annurev-pathol-020117-043854.
[24] Qian XQ, Tang SS, Shen YM, et al. Notch1 affects chemo-resistance through regulating epithelial-mesenchymal transition(EMT)in epithelial ovarian cancer cells[J]. Int J Med Sci, 2020, 17(9): 1215-1223.
[25] Wang Z, Liu Y, Wang M, et al. Effects of miR-492 on migration, invasion, EMT and prognosis in ovarian cancer by targeting SOX7[J]. J buon, 2020, 25(2): 797-804.
[26] Zhao G, Guo Y, Chen Z, et al. miR-203 functions as a tumor Suppressor by inhibiting epithelial to mesenchymal transition in ovarian cancer[J]. J Cancer Sci Ther, 2015, 7(2): 34-43.
[1] 王琳琳 孙美丽 孙玉萍 张楠 刘传勇. 中心体α-微管蛋白、γ-微管蛋白在脑胶质瘤中的表达及其与Survivin表达的相关性研究[J]. 山东大学学报(医学版), 2209, 47(6): 103-.
[2] 袁宗怀,潘广晔,迟曰梅,安传国,张永刚. 孟德尔随机化分析低级别浆液性卵巢癌与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(1): 99-107.
[3] 金珊,高杰,谢玉姣,展垚,杜甜甜,王传新. 甲基转移酶PRMT5稳定USP15促进乳腺癌发生发展的作用[J]. 山东大学学报 (医学版), 2023, 61(7): 1-11.
[4] 何静,严如根,武志红,李长忠. 消癥抑癌方对卵巢癌SKOV3细胞增殖、迁移的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 1-10.
[5] 焦光丽,石子馨,陈蓉,宋亚博,杨飞,崔书君. 基于增强CT影像组学预测卵巢癌患者铂类药物敏感性[J]. 山东大学学报 (医学版), 2023, 61(12): 62-69.
[6] 张艺馨,赵玉立,封丽. 超声特征及术前CA-125联合对51例卵巢交界性及Ⅰ期恶性肿瘤的鉴别诊断[J]. 山东大学学报 (医学版), 2022, 60(7): 104-109.
[7] 林雪艳,张灿灿,田民乐,田永杰. 聚腺苷酸二磷酸核糖聚合酶-1在子宫内膜异位症中的表达及意义[J]. 山东大学学报 (医学版), 2022, 60(2): 27-31.
[8] 哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[9] 陈君宇, 曹冬焱. 以脑梗为首发的卵巢癌病例报告[J]. 山东大学学报 (医学版), 2021, 59(5): 110-112.
[10] 罗慧臣,胡丹慧,张济. miR-203-3p靶向TREM1基因调控TGF-β1/p38MAPK信号通路对狼疮性肾炎小鼠肾小管上皮细胞增殖和凋亡的影响[J]. 山东大学学报 (医学版), 2021, 59(3): 18-25.
[11] 薛源,林雪艳,徐歌,田永杰. 低氧诱导因子-1α在子宫内膜异位症患者血清中的表达和对在位子宫内膜间质细胞上皮-间质转化的影响[J]. 山东大学学报 (医学版), 2021, 59(2): 41-47.
[12] 王正阳,夏艳,师凯旋,陶琨,王小杰. 曲美替尼在卵巢癌中对PAX8的表达作用[J]. 山东大学学报 (医学版), 2021, 59(10): 25-31.
[13] 刘崇东,娄彤,董靖. 子宫内膜异位症恶变[J]. 山东大学学报 (医学版), 2019, 57(6): 27-32.
[14] 关红卫,李娟,孙锐,刘婕,李长忠. 乌苯美司对卵巢癌A2780细胞的生物学影响[J]. 山东大学学报 (医学版), 2019, 57(12): 46-51.
[15] 朱爱国,马振敕,王健. 利用上皮源性卵巢癌预后的多基因信息建立预测预后模型[J]. 山东大学学报 (医学版), 2019, 57(10): 80-85.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发